Fig. 6: MLCK210 deletion inhibits tumor inflammation and tumor growth.

a Schematic of fluorescent myeloid cell adoptive transfer into tumor bearing animals and method of analysis. Quantification of transferred cells was by single color flow cytometry. b Number of CFDA-labelled WT and Mlck210^−/− CD11b+ cells in tumors 2 h or 24 h after adoptive transfer into mice (n = 3 mice), *p = 0.0011 2 h and *p < 0.0001 24 h WT vs Mlck210^−/− by t-test. c Number of CFDA-labelled WT and Mlck210^−/− CD11b+ cells in spleens 2 h or 24 h after adoptive transfer into mice (n = 3 mice), p = 0.9952 2 h and p = 0.727 24 h WT vs Mlck210^−/− by t-test. d Number of CFDA-labelled control All Stars and Mylk siRNA-transfected CD11b+ cells in tumors 2 h after adoptive transfer into mice (n = 3 mice), *p = 0.011 All Stars vs Mylk siRNA-transfected by t-test. e Number of CFDA-labelled control All Stars and Mylk siRNA-transfected CD11b+ cells in spleens 2 h after adoptive transfer into mice (n = 3 mice). Significance testing by one-way Anova with Tukey’s posthoc testing. f Schematic of LLC lung tumor implantation and growth. g–i Mean ± SEM tumor volume over time (g), endpoint volume *p = 0.0003 (h), and weight *p < 0.0001 (i) of LLC tumors implanted in WT (n = 8 mice) and Mlck210^−/− mice (n = 8 mice). j Schematic of LMP pancreatic carcinoma lung tumor implantation and growth. k Time course of pancreatic ductal adenocarcinoma (LMP) tumor growth in WT and Mlck210^−/− tumors (n = 4 mice). l Weight of pancreatic ductal adenocarcinoma tumors from in WT and Mlck210^−/− tumors (n = 4 mice) *p = 0.0019 for WT vs Mlck210^−/− BM. m FACs profiles of myeloid cells in WT and Mlck210^−/− LLC tumors. For Facs gating scheme see Supplementary Fig. 7a. n Quantification of myeloid cells in WT and Mlck210^−/− LLC tumors (n = 4 mice). Significance testing was performed by unpaired two-sample Student’s t-test. Data are presented as mean values ± SEM. Experiments were performed twice. Source data are provided with this article as a Source Data file.